Literature DB >> 22246089

A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita.

M A Kharfan-Dabaja, Z K Otrock, A Bacigalupo, R A Mahfouz, F Geara, A Bazarbachi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22246089     DOI： 10.1038/bmt.2011.257

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  5 in total

1.  Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.

Authors:  M Brown; D Myers; N Shreve; R Rahmetullah; M Radhi
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

Review 2.  Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722

3.  A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Adam S Nelson; Rebecca A Marsh; Kasiani C Myers; Stella M Davies; Sonata Jodele; Tracey A O'Brien; Parinda A Mehta
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-01       Impact factor: 5.742

Review 4.  Molecular insight of dyskeratosis congenita: Defects in telomere length homeostasis.

Authors:  Saeed Dorgaleleh; Karim Naghipoor; Zahra Hajimohammadi; Farzad Dastaviz; Morteza Oladnabi
Journal:  J Clin Transl Res       Date:  2022-01-03

Review 5.  The diagnosis and treatment of dyskeratosis congenita: a review.

Authors:  M Soledad Fernández García; Julie Teruya-Feldstein
Journal:  J Blood Med       Date:  2014-08-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.